林奇综合征结直肠癌生存结局与次全/全结肠切除术后异时瘤发生率:Meta分析
该系统综述与Meta分析纳入15项原始研究,评估林奇综合征结直肠癌患者的生存结局及异时瘤发生率。5年、10年、15年总生存率分别约为89.5%、80.5%、70%;异时瘤发生率为12%至33%,次全/全结肠切除术患者显著更低(0-6%)。
要点
- 林奇综合征结直肠癌5年总生存率约89.5%,10年约80.5%,15年约70%。
- 异时瘤发生率随随访延长为12%至33%,次全/全结肠切除术后降至0-6%。
- 5年总生存率在性别、年龄、MMR基因及肿瘤部位间无显著差异。
核心结论
- 林奇综合征结直肠癌患者总生存率5年约90%、10年约80%、15年约70%。
- 异时瘤发生率在随访至15年时约为10%至30%,次全/全结肠切除术可显著降低该风险。
研究设计与样本
- 系统检索Ovid的MEDLINE、Embase、Cochrane系统综述数据库、ACP Journal Club、DARE及Clinical Trials数据库,自建库至2021年2月。
- 遵循PRISMA报告规范,采用随机效应模型合并数据,使用RevMan v.5.3进行统计分析,所有P值均为双侧。
- 从1942项研究中纳入15项符合标准的研究进行定性及定量合成。
主要发现
- 单因素Meta回归分析显示5年总生存率在性别、年龄、MLH1、MSH2、MSH6及肿瘤部位(右半 versus 左半结肠)间无统计学显著差异。
- 异时瘤发生率为12%至33%,随访期长达15年,在行次全/全结肠切除术的患者中显著更低(0-6%)。
临床怎么用
- 林奇综合征结直肠癌患者长期生存较好,但异时瘤风险持续存在,需长期随访监测。
- 次全/全结肠切除术可显著降低异时瘤发生率,可作为林奇综合征结直肠癌手术方式选择的参考。
局限性
- 纳入研究间存在显著异质性(5年、10年、15年总生存率的I²分别为89%、81%、93%)。
- 15年总生存率置信区间宽(33.7%-91.5%),提示该时间点估计不确定性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lynch syndrome is associated with the most common form of heritable bowel cancer. There remains limited level 1 evidence on survival outcomes and rate of metachronous tumor associated with Lynch syndrome colorectal cancer. METHODS: A systematic literature search of original studies was performed on Ovid searching MEDLINE, Embase, Cochrane Database of Systematic Reviews, American College of Physicians ACP Journal Club, Database of Abstracts of Reviews of Effects DARE, and Clinical Trials databases from inception of database to February 2021. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline was followed. The data were pooled using a random-effects model. All of the P values were 2-tailed, and statistical analysis was performed using RevMan v. 5.3 Cochrane Collaboration. RESULTS: From 1,942 studies, 15 studies met the inclusion criteria and were included for qualitative and quantitative synthesis. The five-year overall survival was 89.5% (82.0-94.1%), P < .01; I2 = 89%. The ten-year overall survival was 80.5% (68.7-88.6%), P < .01; I2 = 81%. The fifteen-year overall survival was 70% (33.7%-91.5%), P < .01; I2 = 93%. Univariate meta-regression analysis showed no statistically significant difference in 5-year overall survival by sex, age, MLH1, MSH2, MSH6, nor tumor location (right versus left colon). The metachronous tumor rate was 12% to 33% with a follow-up period of up to 15 years, significantly lower in patients who underwent subtotal/total colectomy (0-6%). CONCLUSION: The overall survival of patients with colorectal cancer with Lynch syndrome was approximately 90% at 5 years, 80% at 10 years, and 70% at 15 years. The metachronous tumor rate was approximately 10% to 30% at up to 15 years, significantly improved by subtotal/total colectomy.
引用
- Toh JWT, Hui N, Collins G, et al. Survival outcomes associated with Lynch syndrome colorectal cancer and metachronous rate after subtotal/total versus segmental colectomy: Meta-analysis. Surgery. 2022. PMID: 36031446. doi:10.1016/j.surg.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。